Modulation of Tumor-Associated Macrophages (TAM) Phenotype by Platelet-Activating Factor (PAF) Receptor

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Platelet-activating factor (PAF) is implicated in tumor pathogenesis.
• PAF exerts its effects via the PAF receptor (PAFR), present on tumor and immune cells.
• The role of leukocyte-expressed PAFR in tumor growth is not fully understood.

Purpose of the Study:

• To investigate the role of PAFR on infiltrating leukocytes in tumor progression.
• To determine how PAFR expression in leukocytes affects the tumor immune microenvironment.
• To analyze the impact of PAFR blockade on tumor growth in vivo.

Main Methods:

• Utilized PAFR knockout (KO) and wild-type (WT) mice implanted with TC-1 carcinoma or B16F10 melanoma.
• Analyzed leukocyte infiltration (neutrophils, CD8+, CD4+ T cells, M1/M2 macrophages) in tumors.
• Assessed macrophage function (iNOS, arginase activity, IL10 expression) in isolated tumor-infiltrating macrophages.

Main Results:

• Tumor growth was significantly reduced in PAFR KO mice compared to WT mice for both tumor types.
• PAFR KO tumors showed increased infiltration of neutrophils, CD8+ T cells (B16F10), and CD4+ T cells (TC-1).
• PAFR KO tumors exhibited a higher M1-like to M2-like macrophage ratio, with decreased arginase activity and IL10, and increased iNOS in macrophages.

Conclusions:

• Endogenous PAF-like molecules binding to PAFR on macrophages promote tumor growth by inducing an M2-like phenotype.
• Targeting PAFR on tumor-infiltrating leukocytes, particularly macrophages, represents a potential therapeutic strategy in cancer.
• Modulating the immune microenvironment via PAFR blockade can inhibit tumor progression.